Navigation Links
OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Safe in a Broad Population of Patients with Primary PCI for STEMI
Date:9/22/2009

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- OrbusNeich announced today that interim data from a prospective registry showed good safety in a broad population of patients that underwent primary percutaneous coronary intervention (PCI) and implantation of the company's Genous Bio-engineered R stent for ST-elevation myocardial infarction (STEMI).

In the study of 652 consecutive STEMI patients, the rate of major adverse cardiac events (MACE) was 6.7 percent and the rate of subacute thrombosis was 1.1 percent at 30 days follow up. The interim data are presented in a poster by Jan-Henk Dambrink, M.D., Ph.D., of the Isala Klinieken, Zwolle, Netherlands, at the Transcatheter Therapeutics Conference in San Francisco.

"STEMI often presents challenges to interventional cardiologists as the condition can result in delayed stent endothelialization and lead to thrombosis with drug eluting stents," said Dambrink. "The interim data further support the safety profile of the Genous Bio-engineered R stent in this patient population as we confirm the low subacute stent thrombosis rate seen in several large trials for the Genous Bio-engineered R stent."

Harry Suryapranata, M.D., Ph.D., director of Diagram Clinical Research, Department of Cardiology, Isala Klinieken, added: "The interim results reflect a similar finding in a study of the Genous stent in 321 STEMI patients conducted at National University Hospital in Singapore. In the Singapore study, the early stent thrombosis rate was 0.9% with no further thrombotic events out to 12 months follow up."

Eleven percent of the patients in the study of 652 consecutive STEMI patients were diabetic, 41 percent had an anterior infarction, six percent were in heart failure, and six percent received an intra-aortic balloon pump (IABP). Half of the 23 patients who died were initial survivors of out of
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports
2. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients
3. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
4. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
5. New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer
6. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
7. Indian Stem Cell Trial to Broaden Diabetic Foot Inclusion Criteria
8. Mirus Bio Releases for Sale TransIT(R)-2020; a New Broad Spectrum, Animal-Free Transfection Reagent to Go Head to Head With FuGENE(R) HD and Lipofectamine(TM) 2000
9. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
10. Bion Announces Approval of New U.S. Patent that Broadens Protection for the Companys Livestock Waste Environmental Treatment Processes
11. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... YORK , April 30, 2015 The following ... Board of Directors of China Cord Blood Corp (NYSE: ... the special committee of the independent directors of China Cord ... low privatization offer of $6.40 per share from Golden Meditech ... at $6.40 per share would greatly benefit Golden Med and ...
(Date:4/30/2015)... April 30, 2015 - ... Biotechnology Company   Shire (LSE: SHP, ... three months to March 31, 2015. ... million +9% +13% Total revenues $1,488 million +11% +15% ... GAAP operating income from continuing operations $475 million +55% ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
(Date:4/29/2015)... , April 29, 2015   Doximity , the ... all US doctors as members, announced a new, instant ... "Apply Using Doximity." With one click, all US physicians ... curriculum vitae (CV) for an open job opportunity, and ... Eighty seven percent of physicians are open ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... HIV Vaccine ... ... (Nasdaq: MGRM ) today announced that company,researchers have co-authored with ... the Keystone HIV,Vaccines: Progress and Prospects Symposium in Banff, Alberta., ...
... -- Third Sequential Profitable Quarter -- -- ... ET --, BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech ... announced unaudited,financial results for the three months and twelve months ... full year 2007 sales of $33.5 million, up 118% year-over-year ...
... CHICAGO, March 29 Boston,Scientific Corporation (NYSE: ... two-year data from more than 7,000 patients in ... to evaluate the safety performance of the,TAXUS(R) Express2(TM) ... practice. Outcomes through two years in the simple-,use ...
Cached Biology Technology:Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 2Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 3Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 4Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 2Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 3Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 4Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 5Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 6Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 7Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results 8Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 2Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 3Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 4
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... by 2100 and potentially more than 8C by 2200 if ... published in Nature . Scientists found global climate is ... The research also appears to solve one of the great ... whether this will have a positive or negative effect on ...
... for artery in vascular transplantation, but it remains unclear whether ... A recent study reported in the Neural Regeneration Research ... decrease at 7 200 seconds was similar between the middle ... stress of 18.7 kPa or 22.5 kPa. However, the strain ...
... trees lose ground to deforestation and urban sprawl, one development ... winter cold snaps have enabled them to conquer new territory ... 28 years of satellite data from the Smithsonian Environmental Research ... the Proceedings of the National Academy of Sciences . ...
Cached Biology News:Cloud mystery solved: Global temperatures to rise at least 4C by 2100 2Climate change spurs tropical mangroves to expand in the north 2
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Quartz-Halogen, 100 W, High Intensity...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
Biology Products: